Medical Marijuana Patient and Caregiver Notification Statement: Trulieve Immediately Reinstates Previously Recalled Vaporizer Cartridge Sales in Pennsylvania
TALLAHASSEE, Fla., June 3, 2022 – Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced it is immediately reinstating sales of botanically-derived terpene vaporizer cartridges in Pennsylvania. The Medical Marijuana Access & Patient Safety, Inc. (MMAPS), a coalition of patients and the medical cannabis industry, successfully secured a preliminary injunction against the Pennsylvania Department of Health (DOH) statewide recall of these products.
The Trulieve products impacted by the recall were its Modern Flower and Liquid Moxie brands containing botanically-derived terpenes in the form of vaporizer cartridges.
"This victory is a win for medical marijuana patients in Pennsylvania," said Trulieve’s Chief Executive Officer Kim Rivers, "This decision allows medical marijuana patients in the Commonwealth to have continued access to a proven and tested medication. The previously recalled vaporizer cartridges containing terpenes derived from botanical sources had been approved by the Pennsylvania Department of Health for more than four years and are currently being used safely in other states.”
On June 2, 2022, the Commonwealth Court of Pennsylvania granted the preliminary injunction requested by MMAPS and ruled that DOH is enjoined from enforcing the February 4, 2022 Terpene Recall Mandate that required Grower/Processors to recall thousands of vaporizer cartridges containing terpenes derived from botanical sources not cultivated within the permitted facilities.
As a result of the ruling, the recalled products may now return to dispensary shelves to be sold to medical marijuana patients in Pennsylvania. The ruling in part noted that medical marijuana patients would suffer immediate and irreparable harm from enforcement of the Terpene Recall Mandate and that the DOH did not provide sufficient evidence to prove that the recalled products posed harm to Pennsylvania medical marijuana patients.
All Trulieve products returned to dispensary shelves have passed state mandated third party testing and contain ingredients compliant with Act 16’s requirement that excipients be pharmaceutical grade or generally regarded as safe (GRAS) by the FDA.
The DOH has stated it may appeal the ruling which will again put these products out of reach of medical marijuana patients. Trulieve will continue to fight for medical marijuana patient access to products that are tested and effective.
Trulieve operates dispensaries located in the following communities around the Commonwealth: Camp Hill, Coatesville, Cranberry Township, Devon, Harrisburg, Johnstown, King of Prussia, Pittsburgh, Philadelphia, Reading, Scranton, Washington, Whitehall, York and Zelienople.
To find a location or to learn how to become a registered patient, visit Trulieve.com, follow us on Instagram at @trulieve_pa or connect with Trulieve PA on Facebook.
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Christine Hersey, Executive Director of Investor Relations
+1 (424) 202-0210
Rob Kremer, Executive Director of Corporate Communications
+1 (404) 218-3077